Avacincaptad pegol shows significant reduction in GA lesion growth over two years
Izervay (avacincaptad pegol intravitreal solution; Astellas Pharma) demonstrated positive results in the GATHER2 Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), according to data presented at AAO 2023.
The study showed that Izervay, administered either every month or every-other-month, significantly reduced the rate of GA lesion growth compared to a sham treatment over the course of two years. In addition, Izervay was well-tolerated with only minor cases of side effects reported.
Although the trial did not meet the specific objective related to vision loss, these findings represent a significant advancement in the treatment of GA associated with AMD, providing hope for improved outcomes for patients in the future.
Read the full press release from Astellas here.
This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.
Related Content
